Advertisement

Evaluation of the safety of ivermectin-praziquantel administered orally to pregnant mares

Patrick MercierMedical Department, Virbac (SA) Laboratories, 06511 Carros Cedex-France.
Present address is Virbac S.A. 13 ièmeRue L.I.D., BP 27, 06511 Carros Cedex, France.

Search for other papers by Patrick Mercier in
Current site
Google Scholar
PubMed
Close
 DVM
,
Francisco Alves-BrancoConsultorio Médico Veterinario, Bagé, Rio Grande do Sul, RS Brazil.
Present address is Consultorio Médico Veterinario, Rua José do Patrocinio, N o115 CEP: 96.415-500, Bagé-RS Brazil.

Search for other papers by Francisco Alves-Branco in
Current site
Google Scholar
PubMed
Close
 DVM, MSc
,
Maria de Fatima SapperConsultorio Médico Veterinario, Bagé, Rio Grande do Sul, RS Brazil.
Present address is Consultorio Médico Veterinario, Rua José do Patrocinio, N o115 CEP: 96.415- 500, Bagé-RS Brazil.

Search for other papers by Maria de Fatima Sapper in
Current site
Google Scholar
PubMed
Close
 DVM, MSc
, and
Christopher Roger WhiteSao-Judas Tadeu, 575 Bagé, RS Brazil.
Present address is Virbac do Brasil Laboratories, Av. Eng. Eusébio Stevaux, 1368 Jurubatuba, Sao- Paulo, SP Brazil.

Search for other papers by Christopher Roger White in
Current site
Google Scholar
PubMed
Close
 DVM

Abstract

Objective—To evaluate the safety of an orally administered ivermectin and praziquantel paste with regard to variables associated with clinical findings, parturition, lactation, maternal care, and neonate viability in pregnant mares.

Animals—40 pregnant mares.

Procedure—Mares were randomly allocated into treatment (n = 20) and control (20) groups and administered a placebo or 3 times the therapeutic dosage of ivermectin (0.6 mg/kg) and praziquantel (4.5 mg/kg) at 14-day intervals until parturition. Physical examinations were performed on mares and their foals after parturition (on postpartum days 30, 60, and 90) to identify any drug-related effects. As an aid in assessing general health, hematologic and serum biochemical analyses were performed monthly on the mares.

Results—In blood constituents, minor alterations that were not biologically important were observed. Reproductive performance was not affected by the unusual treatment duration or high dosage, although the drugs were administered during a crucial period of equine embryonic development (30 to 60 days). Neither adverse effects on mares nor abortions occurred. Follow-up evaluations of the foals for a 3- month period did not detect any abnormalities.

Conclusions and Clinical Relevance—Administration of the ivermectin-praziquantel paste appears to be safe in pregnant mares and their foals. (Am J Vet Res 2003;64:1221–1224)

Abstract

Objective—To evaluate the safety of an orally administered ivermectin and praziquantel paste with regard to variables associated with clinical findings, parturition, lactation, maternal care, and neonate viability in pregnant mares.

Animals—40 pregnant mares.

Procedure—Mares were randomly allocated into treatment (n = 20) and control (20) groups and administered a placebo or 3 times the therapeutic dosage of ivermectin (0.6 mg/kg) and praziquantel (4.5 mg/kg) at 14-day intervals until parturition. Physical examinations were performed on mares and their foals after parturition (on postpartum days 30, 60, and 90) to identify any drug-related effects. As an aid in assessing general health, hematologic and serum biochemical analyses were performed monthly on the mares.

Results—In blood constituents, minor alterations that were not biologically important were observed. Reproductive performance was not affected by the unusual treatment duration or high dosage, although the drugs were administered during a crucial period of equine embryonic development (30 to 60 days). Neither adverse effects on mares nor abortions occurred. Follow-up evaluations of the foals for a 3- month period did not detect any abnormalities.

Conclusions and Clinical Relevance—Administration of the ivermectin-praziquantel paste appears to be safe in pregnant mares and their foals. (Am J Vet Res 2003;64:1221–1224)